

Practitioner's Docket No. MWH-0006US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Denton, R. Rex; Kliem, Stefanie E.; Nandabalan, Krishnan; and
Stephens, J. Claiborne

Application No.: To Be Assigned
Filed: February 06, 2002

Group No.: 1632
Examiner: Anne-Marie Baker, Ph.D.

For: Drug Target Isogenes: Polymorphisms in the 5-Hydroxytryptamine Receptor 1A Gene

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231


STATEMENT ACCOMPANYING SEQUENCE LISTING
(CFR 1.821(f))

The undersigned hereby states upon information and belief that the information recorded in the computer readable form of the Sequence Listing submitted herewith is identical to the originally submitted written Sequence Listing and computer readable form as filed with the International PCT application on August 1, 2000, Serial No. PCT/US00/40519. No new matter is contained in this submission.

Respectfully submitted,

Date: Feb. 6, 2002

Reg. No.: 47,562
Tel. No.: 203-786-3473


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
USA

Practitioner's Docket No. MWH-0006US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Denton, R. Rex; Kliem, Stefanie E.; Nandabalan, Krishnan; and
Stephens, J. Claiborne

Application No.: To Be Assigned
Filed: February 06, 2002

Group No.: 1632
Examiner: Anne-Marie Baker, Ph.D.

For: Drug Target Isogenes: Polymorphisms in the 5-Hydroxytryptamine Receptor 1A Gene

Assistant Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR EXPEDITED EXAMINATION OF NATIONAL STAGE APPLICATION
PURSUANT TO 35 U.S.C. 371 (f) AND 37 C.F.R. 1.496 (b)

Enclosed please find:

(a) Application filed under 35 U.S.C. 371(c).

Applicants herein file a National Application pursuant to 35 U.S.C. 371. The claims in this Application are identical to the claims in the International Application PCT/US00/40519 filed on August 1, 2001 and amended by a PCT Article 34 Amendment on March 5, 2001. The United States Patent and Trademark Office acting as the International Preliminary Examination Authority has indicated in the International Preliminary Examination Report that the claims in the International Application, as amended, satisfy the criteria of PCT Articles 33(1)-(4) as to novelty, inventive step, and industrial applicability.

(b) Basic National Fee

The basic national fee pursuant to 37 C.F.R. 1.492(a)(4) is enclosed.


Applicants believe that they have met the requirements of 35 U.S.C. 371(f) and 37 C.F.R. 1.496 (b) with the enclosed submission and respectfully request that this National Stage Application be examined out of turn.

Should any questions arise, or if Applicants or Applicants' Agent can facilitate examination of this application, it is respectfully requested that the undersigned Agent be contacted so that any remaining issues can be resolved.

Date: Feb 06, 2002

Reg. No.: 47,562
Tel. No.: 203-786-3473

Respectfully submitted,



Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
USA